Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.01 billion. The enterprise value is $1.54 billion.
| Market Cap | 2.01B |
| Enterprise Value | 1.54B |
Important Dates
The last earnings date was Monday, November 2, 2026, after market close.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 623.37 million shares outstanding. The number of shares has increased by 32.56% in one year.
| Current Share Class | 622.76M |
| Shares Outstanding | 623.37M |
| Shares Change (YoY) | +32.56% |
| Shares Change (QoQ) | +1.98% |
| Owned by Insiders (%) | 2.55% |
| Owned by Institutions (%) | 58.85% |
| Float | 606.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.42 |
| Forward PS | 47.80 |
| PB Ratio | 2.06 |
| P/TBV Ratio | 4.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.01, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.01 |
| Quick Ratio | 4.75 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -548.07 |
Financial Efficiency
Return on equity (ROE) is -48.72% and return on invested capital (ROIC) is -29.68%.
| Return on Equity (ROE) | -48.72% |
| Return on Assets (ROA) | -23.89% |
| Return on Invested Capital (ROIC) | -29.68% |
| Return on Capital Employed (ROCE) | -45.59% |
| Weighted Average Cost of Capital (WACC) | 10.25% |
| Revenue Per Employee | $113,720 |
| Profits Per Employee | -$792,778 |
| Employee Count | 600 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.56M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.75% in the last 52 weeks. The beta is 1.15, so RXRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -30.75% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 3.48 |
| Relative Strength Index (RSI) | 40.11 |
| Average Volume (20 Days) | 20,275,079 |
Short Selling Information
The latest short interest is 161.93 million, so 25.98% of the outstanding shares have been sold short.
| Short Interest | 161.93M |
| Short Previous Month | 157.94M |
| Short % of Shares Out | 25.98% |
| Short % of Float | 26.68% |
| Short Ratio (days to cover) | 5.28 |
Income Statement
In the last 12 months, RXRX had revenue of $68.23 million and -$475.67 million in losses. Loss per share was -$0.89.
| Revenue | 68.23M |
| Gross Profit | -352.64M |
| Operating Income | -500.94M |
| Pretax Income | -480.23M |
| Net Income | -475.67M |
| EBITDA | -427.09M |
| EBIT | -500.94M |
| Loss Per Share | -$0.89 |
Balance Sheet
The company has $549.85 million in cash and $74.70 million in debt, with a net cash position of $475.15 million or $0.76 per share.
| Cash & Cash Equivalents | 549.85M |
| Total Debt | 74.70M |
| Net Cash | 475.15M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 905.81M |
| Book Value Per Share | 1.61 |
| Working Capital | 493.10M |
Cash Flow
In the last 12 months, operating cash flow was -$310.53 million and capital expenditures -$1.95 million, giving a free cash flow of -$312.48 million.
| Operating Cash Flow | -310.53M |
| Capital Expenditures | -1.95M |
| Depreciation & Amortization | 73.85M |
| Net Borrowing | -8.92M |
| Free Cash Flow | -312.48M |
| FCF Per Share | -$0.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | -734.17% |
| Pretax Margin | -703.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.56% |
| Shareholder Yield | -32.56% |
| Earnings Yield | -27.70% |
| FCF Yield | -15.05% |
Analyst Forecast
The average price target for RXRX is $7.32, which is 126.53% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.32 |
| Price Target Difference | 126.53% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -15.24% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.18 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.18 |
| Piotroski F-Score | 5 |